Scientific publications for BioPredictive non-invasive diagnostics

Peer-reviewed studies validating BioPredictive blood-test diagnostics for liver disease — from first-in-class development cohorts to long-term meta-analyses.

133/433 Matches for
“Metabolic risk factors”

“Metabolic risk factors” Clear all
  1. Childhood/adult-onset lysosomal acid lipase deficiency: A serious metabolic and vascular phenotype beyond liver disease-four new pediatric cases.

    Poinsot P et al. · J Clin Lipidol · 2017 Match 100

    …However, late-onset LALD should be considered as a systemic metabolic disease…

    FibroTest Metabolic

  2. Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.

    Pais R et al. · Eur J Intern Med · 2015 Match 100

    …In CHB, metabolic risk factors and HOMA-IR were not associated with…

    FibroTest SteatoTest HBV HCV +1

  3. Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.

    Perazzo H et al. · Aliment Pharmacol Ther · 2014 Match 100

    …The cardiovascular Framingham-risk score was calculated; advanced fibrosis and severe steatosis…

    FibroTest SteatoTest Metabolic

  4. Impact of steatosis and inflammation definitions on the performance of NASH tests.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2018 Match 99

    ### Background And Aim One of the unmet needs in subjects with metabolic

    ActiTest FibroTest NashTest NashTest-2 +3

  5. Noninvasive Markers of Improvement of Liver Steatosis Achieved by Weight Reduction in Patients with Nonalcoholic Fatty Liver Disease.

    Copaci I et al. · Rom J Intern Med · 2015 Match 99

    …minimal weight loss ALT levels, steatosis, adipokines and cardiovascular risk factors improved.

    SteatoTest Metabolic

  6. EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease.

    European Association for the Study of the Liver (EASL) et al. · Obes Facts · 2016 Match 99

    FibroTest SteatoTest Metabolic

  7. Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease.

    Viglino D et al. · Eur Respir J · 2017 Match 98

    Nonalcoholic fatty liver disease (NAFLD) is independently linked to cardiometabolic morbidity and…

    FibroTest NashTest SteatoTest Metabolic

  8. Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2018 Match 98

    ### Background One of the unmet needs in patients with metabolic risks is…

    FibroTest NashTest SteatoTest Metabolic

  9. Non-invasive diagnosis of steatosis, inflammatory changes and liver fibrosis in patients with non-alcoholic fatty liver diseases. Pilot study.

    Ciećko-Michalska I et al. · Arch Med Sci Atheroscler Dis · 2018 Match 97

    …We compared the prevalence of metabolic disorders and hypertension between women and…

    ActiTest FibroTest SteatoTest Metabolic

  10. Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. Key publication

    Munteanu M et al. · J Gastrointestin Liver Dis · 2008 Match 97

    ActiTest AshTest FibroTest NashTest +6

  11. Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. Review

    Bril F et al. · Diabetes Care · 2017 Match 97

    …It carries both metabolic and liver-specific complications that make its approach…

    FibroTest Metabolic

  12. Non-invasive diagnosis and follow-up of chronic infection with Hepatitis C Virus.

    Tran A et al. · Clin Res Hepatol Gastroenterol · 2022 Match 96

    …without liver comorbidity (alcohol consumption, metabolic syndrome, HBV co-infection etc.) no…

    FibroTest HCV

  13. Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.

    Lemoine M et al. · J Acquir Immune Defic Syndr · 2019 Match 96

    ### Background HIV-monoinfected individuals are at high risk of nonalcoholic fatty liver…

    FibroTest NashTest SteatoTest HIV

  14. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest).

    Poynard T et al. · BMC Gastroenterol · 2010 Match 96

    …prevalence of fibrosis, identifying independent risk factors and to propose screening strategies…

    FibroTest Alcohol HBV HCV +3

  15. Utility of noninvasive methods for the characterization of nonalcoholic liver steatosis in the family practice. The "VARES" Italian multicenter study.

    Grattagliano I et al. · Ann Hepatol · 2013 Match 95

    …with metabolic disturbances and cardiovascular risk. Asymptomatic subjects at risk also should…

    ActiTest FibroTest NashTest SteatoTest +1

  16. Screening for liver fibrosis by using FibroScan(®) and FibroTest in patients with diabetes.

    de Lédinghen V et al. · Dig Liver Dis · 2012 Match 95

    ### Background Patients with diabetes are at risk for nonalcoholic fatty liver disease…

    FibroTest Metabolic

  17. Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19.

    Deckmyn O et al. · Biomedicines · 2022 Match 94

    …haptoglobin are associated with the risk of liver fibrosis, inflammation (NASH), and…

    FibroTest Metabolic

  18. Novel Biomarkers of Grade I Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease.

    Braha A et al. · J Clin Med · 2024 Match 94

    …Prior research has identified a significant association between heart disease and metabolic

    FibroTest Metabolic

  19. Nonalcoholic fatty liver disease, nocturnal hypoxia, and endothelial function in patients with sleep apnea.

    Minville C et al. · Chest · 2014 Match 94

    …By multivariate analysis, independent factors for liver steatosis were, as expected, triglyceride…

    FibroTest NashTest SteatoTest Metabolic

  20. Interferon-γ-inducible protein-10 in chronic hepatitis C: Correlations with insulin resistance, histological features & sustained virological response.

    Crisan D et al. · Indian J Med Res · 2017 Match 93

    ### Background & Objectives One of the multiple factors contributing to virological response in…

    ActiTest FibroTest SteatoTest HCV

  21. Coffee and Caffeine Are Associated With Decreased Risk of Advanced Hepatic Fibrosis Among Patients With Hepatitis C.

    Khalaf N et al. · Clin Gastroenterol Hepatol · 2015 Match 93

    ### Background & Aims Coffee or caffeine has been proposed to protect against hepatic…

    FibroTest HCV

  22. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. Key publication

    Ratziu V et al. · BMC Gastroenterol · 2006 Match 93

    ### Background Liver biopsy is considered as the gold standard for assessing non…

    FibroTest Metabolic

  23. The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. Key publication

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2019 Match 92

    …cases including healthy individuals without risk factors of steatosis as controls, respectively…

    NashTest-2 SteatoTest-2 Metabolic

  24. Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study.

    Denimal D et al. · Cardiovasc Diabetol · 2025 Match 92

    …adjusting for baseline LLACS and risk factors for lower extremity artery disease…

    ActiTest FibroTest NashTest SteatoTest +1

  25. Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.

    López Tórrez SM et al. · Front Nutr · 2024 Match 91

    ### Introduction A prognostic model to predict liver severity in people with metabolic

    FibroTest Metabolic

  26. Non-alcoholic fatty liver disease biomarkers estimate cardiovascular risk based on coronary artery calcium score in type 2 diabetes: a cross-sectional study with two independent cohorts.

    Denimal D et al. · Cardiovasc Diabetol · 2024 Match 91

    …independently of the traditional cardiovascular risk factors included in the SCORE2-Diabetes…

    ActiTest FibroTest NashTest SteatoTest +1

  27. Impact of effective versus sham continuous positive airway pressure on liver injury in obstructive sleep apnoea: Data from randomized trials.

    Jullian-Desayes I et al. · Respirology · 2016 Match 91

    ### Background And Objective Obstructive sleep apnoea (OSA) could be an independent risk

    NashTest SteatoTest Metabolic

  28. Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study.

    Laharie D et al. · J Hepatol · 2010 Match 90

    …Patients with other risk factors for liver disease should be closely monitored…

    FibroTest Other

  29. The impact of bariatric surgery on nonalcoholic fatty liver disease as measured using non-invasive tests.

    Netanel C et al. · Am J Surg · 2021 Match 90

    ### Background Nonalcoholic fatty liver disease (NAFLD) is common in bariatric surgery candidates…

    FibroTest NashTest SteatoTest Metabolic

  30. PNPLA3 polymorphism influences liver fibrosis in unselected patients with type 2 diabetes.

    Petit JM et al. · Liver Int · 2011 Match 90

    ### Context Recently, it has been shown that an allele in the adiponutrin…

    FibroTest Metabolic

  31. Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

    Poynard T et al. · Diagnostics (Basel) · 2025 Match 89

    …In MASLD, trajectories of proxies and incidence against confounding factors used hazard…

    FibroTest-T2D Metabolic

  32. Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers.

    Vermehren J et al. · BMC Gastroenterol · 2012 Match 89

    …The impact of other risk factors, including prolonged exposure to combined antiretroviral…

    FibroTest HCV HIV

  33. Impact of Non-alcoholic Fatty Liver Disease on long-term cardiovascular events and death in Chronic Obstructive Pulmonary Disease.

    Viglino D et al. · Sci Rep · 2018 Match 88

    …NAFLD) both independently increase cardiovascular risk. We hypothesized that NAFLD might increase…

    FibroTest NashTest SteatoTest Metabolic

  34. Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review.

    Harris R et al. · Lancet Gastroenterol Hepatol · 2017 Match 88

    …Investigators from studies targeting patients with risk factors of liver disease, such…

    FibroTest Other

  35. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Key publication

    Poynard T et al. · Comp Hepatol · 2005 Match 88

    …the need for liver biopsy, particularly in patients with metabolic risk factor.

    SteatoTest Alcohol HBV HCV +1

  36. The Higher Prevalence of Non-Alcoholic versus Alcoholic Steatohepatitis in Alcoholics.

    Gruszewska E et al. · Clin Lab · 2015 Match 87

    …steatohepatitis is associated with metabolic risk factors such as diabetes mellitus, dyslipidemia…

    AshTest NashTest Alcohol

  37. Guidelines for the diagnosis of uncomplicated cirrhosis.

    Fontaine H et al. · Gastroenterol Clin Biol · 2007 Match 87

    FibroTest Alcohol HBV HCV +2

  38. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C.

    Poynard T et al. · J Hepatol · 2013 Match 87

    …in cirrhosis cases, and a remaining 5% risk of primary liver cancer.

    FibroTest HCV

  39. Liver fibrosis regression and progression during controlled hepatitis B virus infection among HIV-HBV patients treated with tenofovir disoproxil fumarate in France: a prospective cohort study.

    Boyd A et al. · J Int AIDS Soc · 2017 Match 86

    Risk factors for fibrosis progression (F0-F1-F2 to F3-F4) and…

    FibroTest HBV HIV

  40. Toward non-invasive assessment strategies in autoimmune hepatitis.

    Jerez Diaz D et al. · World J Hepatol · 2025 Match 86

    In this article, we comment on the article by Peta _et al…

    ActiTest FibroTest AIH

  41. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.

    de Lédinghen V et al. · Liver Int · 2012 Match 85

    ### Introduction Recently, a study showed that Controlled Attenuation Parameter (CAP), evaluated with…

    SteatoTest Metabolic

  42. Assessment of allograft fibrosis by transient elastography and noninvasive biomarker scoring systems in liver transplant patients.

    Beckebaum S et al. · Transplantation · 2010 Match 85

    ### Background This prospective, monocentric study was designed to assess the efficacy of…

    FibroTest Alcohol HBV HCV +2

  43. Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study.

    Zelber-Sagi S et al. · Hepatology · 2008 Match 85

    …was associated with a reduced risk for abdominal obesity. Adjusting for sex…

    SteatoTest Metabolic

  44. Screening studies of transient elastography and FibroTest in the general population.

    Poynard T et al. · Lancet Gastroenterol Hepatol · 2017 Match 84

    FibroTest Other

  45. Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population.

    Zelber-Sagi S et al. · Transl Res · 2015 Match 84

    Retrospective studies suggest that coffee consumption may exert beneficial effects in patients…

    FibroTest SteatoTest Metabolic

  46. Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI c'est fini ?".

    Perazzo H et al. · Clin Res Hepatol Gastroenterol · 2014 Match 84

    …with the variability of metabolic risk factors between the different control groups…

    FibroTest Alcohol HBV HCV +1

  47. Management of the patient with SVR. Review

    Terrault NA et al. · J Hepatol · 2016 Match 83

    …such as renal, dermatologic, and metabolic complications. However, not all patients will…

    FibroTest HCV

  48. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data.

    Poynard T et al. · PLoS One · 2012 Match 83

    …Despite more metabolic risk factors in one cohort, results were similar according…

    ActiTest FibroTest NashTest SteatoTest +1

  49. Biomarkers for liver disease in urea cycle disorders.

    Nagamani SCS et al. · Mol Genet Metab · 2021 Match 82

    …with UCDs who are at risk for this complication. ### Trial Registration This…

    ActiTest FibroTest Other

  50. Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis.

    Poynard T et al. · Aliment Pharmacol Ther · 2023 Match 82

    FibroTest-T2D NashTest-T2D SteatoTest-T2D Metabolic

  51. Screening studies of transient elastography and FibroTest in the general population - Authors' reply.

    Ginès P et al. · Lancet Gastroenterol Hepatol · 2017 Match 82

    FibroTest Other

  52. Noninvasive evaluation of NAFLD.

    Castera L et al. · Nat Rev Gastroenterol Hepatol · 2013 Match 81

    …advanced fibrosis are at greatest risk of developing complications of end-stage…

    ActiTest FibroTest NashTest SteatoTest +1

  53. Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes.

    Poynard T et al. · Eur J Gastroenterol Hepatol · 2020 Match 81

    …tests for the diagnostic of metabolic liver disease in patients with type…

    FibroTest NashTest-2 SteatoTest-2 Metabolic

  54. Glycogenic hepatopathy.

    Khoury J et al. · Hepatobiliary Pancreat Dis Int · 2018 Match 81

    ### Background Glycogenic hepatopathy (GH) is a disorder associated with uncontrolled diabetes mellitus…

    FibroTest Metabolic

  55. The product of triglycerides and glucose as biomarker for screening simple steatosis and NASH in asymptomatic women.

    Simental-Mendía LE et al. · Ann Hepatol · 2016 Match 80

    ### Unlabelled Introduction and aim. Given that early identification of non-alcoholic fatty…

    NashTest SteatoTest Metabolic

  56. The non-invasive assessment of hepatic fibrosis.

    Gheorghe G et al. · J Formos Med Assoc · 2021 Match 80

    …of the most relevant prognostic factors. The liver biopsy with the histopathological…

    ActiTest FibroTest Alcohol HBV +2

  57. LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. Key publication

    Poynard T et al. · Aliment Pharmacol Ther · 2019 Match 79

    …proteins (apolipoproteinA1, haptoglobin) with known risk factors (gender, age, gammaglutamyltranspeptidase), and a…

    LCR1 LCR2 Alcohol HBV +4

  58. Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference.

    Peta V et al. · World J Hepatol · 2025 Match 79

    ### Background Noninvasive tests are crucial for the management and follow-up of…

    ActiTest FibroTest AIH

  59. Silymarin in non alcoholic fatty liver disease.

    Cacciapuoti F et al. · World J Hepatol · 2013 Match 79

    …patients affected by NAFLD, main metabolic, hepatic and anti-inflammatory parameters were…

    SteatoTest Metabolic

  60. Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia.

    Ratziu V et al. · Aliment Pharmacol Ther · 2007 Match 78

    …Hyperlipidaemic patients have multiple risk factors of insulin resistance. It is impossible…

    FibroTest NashTest SteatoTest Metabolic

  61. Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia.

    Poynard T et al. · Hepatol Commun · 2023 Match 78

    …survivals before adjusting for confounding factors. With the exception of cholelithiasis in…

    FibroTest

  62. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers.

    Vilar-Gomez E et al. · J Hepatol · 2018 Match 78

    The correct identification of patients at increased risk of non-alcoholic steatohepatitis…

    FibroTest Metabolic

  63. Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard.

    Poynard T et al. · J Hepatol · 2012 Match 77

    …In the volunteers, the false positive risk of biopsy was obtained from…

    FibroTest HCV

  64. Noninvasive procedures to evaluate liver involvement in HIV-1 vertically infected children.

    Rubio A et al. · J Pediatr Gastroenterol Nutr · 2009 Match 77

    …inhibitor drugs were the main risk factors for hepatotoxicity. ### Conclusions : More than…

    FibroTest HIV

  65. Twenty-year protocol liver biopsies: Invasive but useful for the management of liver recipients.

    Sebagh M et al. · J Hepatol · 2012 Match 76

    ### Background & Aims Most liver transplant centres have discontinued the practice of protocol…

    ActiTest FibroTest Alcohol HBV +4

  66. Noninvasive, Blood-Based Biomarkers as Screening Tools for Hepatic Fibrosis in People With Type 2 Diabetes.

    Meritsi A et al. · Clin Diabetes · 2022 Match 76

    ActiTest FibroTest NashTest-2 Metabolic

  67. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference.

    Munteanu M et al. · Aliment Pharmacol Ther · 2016 Match 76

    ### Background Blood tests of liver injury are less well validated in non…

    ActiTest FibroTest SteatoTest Metabolic

  68. Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. Key publication

    Poynard T et al. · Gastroenterol Clin Biol · 2008 Match 75

    This review summarizes the methodological aspects of the interpretation of non-invasive…

    ActiTest FibroTest SteatoTest Alcohol +5

  69. Non-invasive evaluation of liver fibrosis by transient elastography and biochemical markers in elderly inpatients.

    Salles N et al. · Gastroenterol Clin Biol · 2009 Match 75

    ### Aim The objective of this study was to evaluate liver fibrosis using…

    FibroTest

  70. Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy.

    Guiu B et al. · Eur Radiol · 2012 Match 75

    ### Objectives The SteatoTest, fatty liver index (FLI) and hepatic steatosis index (HSI…

    SteatoTest Metabolic

  71. Noninvasive diagnosis in alcohol-related liver disease. Review

    Hadefi A et al. · Health Sci Rep · 2020 Match 74

    ### Background Alcohol-related liver disease (ALD) represents a major cause of death…

    FibroTest Alcohol

  72. Applicability and variability of liver stiffness measurements according to probe position.

    Ingiliz P et al. · World J Gastroenterol · 2009 Match 74

    ### Aim To investigate the liver stiffness measurement (LSM) applicability and variability with…

    FibroTest Alcohol HBV HCV +3

  73. Intestinal failure-associated liver disease in patients with short bowel syndrome: Evaluation by transient elastography.

    Knop V et al. · Nutrition · 2019 Match 73

    …Short intestinal remnant length <100cm appeared to be a risk factor for…

    FibroTest SteatoTest Other

  74. Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers.

    Poynard T et al. · PLoS One · 2008 Match 73

    …high-risk patients. Thereafter, the impact of potential variability factors was assessed…

    FibroTest Alcohol HBV HCV +3

  75. Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods.

    Festi D et al. · Aliment Pharmacol Ther · 2013 Match 73

    ### Background Non-alcoholic fatty liver disease (NAFLD) encompasses a wide spectrum of…

    SteatoTest

  76. Liver fibrosis evaluation using real-time shear wave elastography: applicability and diagnostic performance using methods without a gold standard.

    Poynard T et al. · J Hepatol · 2013 Match 72

    …which had no assessment of factors associated with reliability, and had limited…

    FibroTest Alcohol HBV HCV +3

  77. EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

    European Association for the Study of the Liver · J Hepatol · 2011 Match 72

    ActiTest FibroTest HCV

  78. Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males.

    White DL et al. · Hepatology · 2012 Match 72

    ### Unlabelled Males have strikingly increased risk of advanced liver disease. However, the…

    ActiTest FibroTest HCV

  79. Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV.

    Matta B et al. · Curr HIV/AIDS Rep · 2016 Match 71

    Patients with HIV have a proclivity to develop liver fibrosis, especially when…

    FibroTest HBV HCV HIV

  80. External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV.

    Poynard T et al. · JHEP Rep · 2021 Match 71

    …haptoglobin), known hepatocellular carcinoma (HCC) risk factors (sex, age, and gamma-glutamyl…

    LCR1 LCR2 HCV

  81. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.

    Terrault NA et al. · Hepatology · 2018 Match 70

    ActiTest FibroTest HBV

  82. Hepatotoxicity of tocilizumab and anakinra in rheumatoid arthritis: management decisions.

    Mahamid M et al. · Clin Pharmacol · 2011 Match 70

    …Similarly, the factors involved in decisions regarding discontinuation of treatment and outcome…

    FibroTest Other

  83. The Distribution of Liver Steatosis, Fibrosis, Steatohepatitis and Inflammation Activity in Alcoholics According to FibroMax Test.

    Gudowska M et al. · Adv Clin Exp Med · 2015 Match 70

    ### Background The diagnosis of alcoholic liver diseases is based on the history…

    ActiTest AshTest FibroTest NashTest +2

  84. An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Key publication

    Myers RP et al. · Can J Gastroenterol · 2012 Match 69

    Chronic hepatitis C remains a significant medical and economic burden in Canada…

    FibroTest HCV

  85. American Association for the Study of the Liver

    Match 69

    FibroTest HCV

  86. Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes.

    Poynard T et al. · Aliment Pharmacol Ther · 2021 Match 69

    ### Background One of the unmet needs in patients with type 2 diabetes…

    FibroTest NashTest-2 SteatoTest Metabolic

  87. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication

    European Association for Study of Liver et al. · J Hepatol · 2015 Match 68

    FibroTest Alcohol HBV HCV +3

  88. Racial differences in the association between adiposity measures and the risk of hepatitis C-related liver disease.

    White DL et al. · J Clin Gastroenterol · 2012 Match 68

    …Race-stratified logistic regression was employed to evaluate risk of high fibrosis…

    ActiTest FibroTest HCV

  89. Non-invasive markers for hepatic fibrosis.

    Baranova A et al. · BMC Gastroenterol · 2011 Match 67

    …pathogens, and many other etiologic factors. Current non-invasive methods range from…

    FibroTest Alcohol HBV HCV +3

  90. Personalized management of cirrhosis by non-invasive tests of liver fibrosis.

    Wong GL et al. · Clin Mol Hepatol · 2015 Match 67

    Owing to the high prevalence of various chronic liver diseases, cirrhosis is…

    FibroTest Alcohol HBV HCV +1

  91. Stage of liver fibrosis in patients with congenital bleeding disorders and infected with hepatitis C virus.

    Kucharska M et al. · Pol Arch Intern Med · 2017 Match 67

    …The risk factors for liver fibrosis were analyzed, including demographic factors, HCV…

    FibroTest HCV

  92. Non-invasive Investigations for the Diagnosis of Fontan-Associated Liver Disease in Pediatric and Adult Fontan Patients.

    Fidai A et al. · Front Cardiovasc Med · 2017 Match 66

    Fontan-associated liver disease (FALD) is a serious complication related to the…

    FibroTest Other

  93. Role of Non-hepatic Medical Comorbidity and Functional Limitations in Predicting Mortality in Patients with HCV.

    Natarajan Y et al. · Dig Dis Sci · 2017 Match 66

    …identify HCV patients at high risk for mortality, which could further guide…

    FibroTest HCV

  94. Comparative diagnostic study of biomarkers using FibroMax™ and pathology for prediction of liver steatosis in patients with chronic hepatitis C virus infection: an Egyptian study.

    Fouad A et al. · Int J Gen Med · 2013 Match 66

    ### Background Steatosis is common in patients with hepatitis C virus (HCV) infection…

    HCV

  95. Usefulness of noninvasive tests in nodular regenerative hyperplasia of the liver.

    Laharie D et al. · Eur J Gastroenterol Hepatol · 2010 Match 65

    ### Background The only way to diagnose nodular regenerative hyperplasia (NRH) is liver…

    FibroTest Other

  96. Predictive value of biomarkers of hepatic fibrosis in adult Fontan patients.

    Wu FM et al. · J Heart Lung Transplant · 2017 Match 65

    ### Background Hepatic fibrosis is highly prevalent in individuals with Fontan circulation. FibroSure…

    FibroTest

  97. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease.

    Adams LA et al. · J Gastroenterol Hepatol · 2011 Match 64

    ### Background And Aim Significant hepatic fibrosis is prognostic of liver morbidity and…

    FibroTest Metabolic

  98. Assessment of liver fibrosis and steatosis in PBC with FibroScan, MRI, MR-spectroscopy, and serum markers.

    Friedrich-Rust M et al. · J Clin Gastroenterol · 2010 Match 64

    ### Background In recent years noninvasive methods have been evaluated for the assessment…

    FibroTest SteatoTest Other

  99. The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosis.

    Boursier J et al. · Liver Int · 2009 Match 64

    ### Background And Aims Blood tests and liver stiffness evaluation (LSE) by ultrasonographic…

    FibroTest Alcohol HBV HCV +2

  100. Spleen stiffness measurement by transient elastography to diagnose portal hypertension in children.

    Goldschmidt I et al. · J Pediatr Gastroenterol Nutr · 2014 Match 63

    ### Background The development of esophageal varices is a late complication of chronic…

    FibroTest Other

  101. The use of transient elastography and FibroTest for monitoring hepatotoxicity in patients receiving methotrexate for psoriasis.

    Lynch M et al. · JAMA Dermatol · 2014 Match 63

    ### Importance There is a need for noninvasive tools to monitor hepatotoxicity in…

    FibroTest Other

  102. Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection.

    Calès P et al. · J Hepatol · 2010 Match 63

    ### Background & Aims We compared 5 non-specific and 2 specific blood tests…

    FibroTest HCV HIV

  103. Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy.

    Giannini EG et al. · J Gastroenterol Hepatol · 2015 Match 62

    ### Background And Aim Thrombocytopenia is frequently observed in patients with chronic hepatitis…

    FibroTest HCV

  104. FibroTest and Fibroscan performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate.

    Poynard T et al. · Clin Res Hepatol Gastroenterol · 2011 Match 62

    …appropriate method due to the risk of fibrosis spectrum effect. Furthermore the…

    FibroTest HCV

  105. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Key publication

    AASLD/IDSA HCV Guidance Panel · Hepatology · 2015 Match 61

    ActiTest FibroTest HCV

  106. Validation of the Performance of A1HPV6, a Triage Blood Test for the Early Diagnosis and Prognosis of SARS-CoV-2 Infection.

    Maisonnasse P et al. · Gastro Hep Adv · 2022 Match 61

    …We have constructed and validated a multivariable risk calculator (A1HPV6) integrating A1…

    FibroTest COVID

  107. Performances of Elasto-FibroTest(®), a combination between FibroTest(®) and liver stiffness measurements for assessing the stage of liver fibrosis in patients with chronic hepatitis C.

    Poynard T et al. · Clin Res Hepatol Gastroenterol · 2012 Match 61

    ### Background FibroTest(®) (FT), and liver stiffness measurement (LSM) are the most validated…

    Elasto-FibroTest FibroTest HCV

  108. Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification.

    Zelber-Sagi S et al. · World J Gastroenterol · 2013 Match 60

    ### Aim To compare noninvasive methods presently used for steatosis detection and quantification…

    SteatoTest Metabolic

  109. Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population.

    Poynard T et al. · J Hepatol · 2012 Match 60

    …fibrosis progression in chronic liver diseases and better identification of risk factors.

    FibroTest Alcohol HBV HCV +1

  110. The diagnostic value of combining carbohydrate-deficient transferrin, fibrosis, and steatosis biomarkers for the prediction of excessive alcohol consumption.

    Imbert-Bismut F et al. · Eur J Gastroenterol Hepatol · 2009 Match 60

    ### Background And Aim The validity of biomarkers of excessive alcohol drinking (EAD…

    FibroTest SteatoTest Alcohol

  111. Non-invasive measurement of liver and pancreas fibrosis in patients with cystic fibrosis.

    Friedrich-Rust M et al. · J Cyst Fibros · 2013 Match 59

    ### Background Patients with cystic fibrosis (CF) have a relevant morbidity and mortality…

    FibroTest Other

  112. Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest®) and elastography (FibroScan®).

    Poynard T et al. · J Hepatol · 2014 Match 59

    …incidence of cirrhosis increased, with a remaining 5.8% risk of HCC.

    ActiTest FibroTest HBV

  113. Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B.

    Poynard T et al. · Curr Hepat Rep · 2011 Match 58

    …Sensitivity analysis assessed the impact of several factors, including authors' independence, length…

    FibroTest HBV

  114. Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers.

    Castéra L et al. · Aliment Pharmacol Ther · 2011 Match 58

    ### Background Non invasive methods for fibrosis evaluation remain to be validated longitudinally…

    FibroTest HBV

  115. Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery.

    Peta V et al. · PLoS One · 2017 Match 58

    ### Background There is a clear need for better biomarkers of drug-induced…

    ActiTest FibroTest Other

  116. Effects of patient factors on noninvasive liver stiffness measurement using acoustic radiation force impulse elastography in patients with chronic hepatitis C.

    Chen SH et al. · BMC Gastroenterol · 2012 Match 57

    ### Background Previous research has shown variation in the effects of patient factors

    FibroTest HCV

  117. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. Key publication

    Poynard T et al. · BMC Gastroenterol · 2006 Match 57

    ### Background Liver biopsy is considered the gold standard for assessing histologic lesions…

    NashTest Metabolic

  118. Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease.

    Thiele M et al. · Gastroenterology · 2018 Match 57

    ### Background & Aims Alcohol is the leading cause of cirrhosis and liver-related…

    FibroTest Alcohol

  119. Non-invasive diagnosis and follow-up of portal hypertension.

    Thabut D et al. · Clin Res Hepatol Gastroenterol · 2022 Match 56

    …Patients with cACLD are at high risk of liver-related morbidity and…

    FibroTest Alcohol HBV HCV +1

  120. Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis.

    Castera L · J Viral Hepat · 2009 Match 56

    The limitations of liver biopsy (invasive procedure, sampling errors, inter-observer variability…

    FibroTest HBV HCV HIV

  121. An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. Key publication

    Ngo Y et al. · PLoS One · 2008 Match 55

    …The adjustment factors were age, sex, HBeAg, ethnic origin, alcohol consumption, HIV…

    ActiTest FibroTest HCV

  122. [Biomarkers for liver fibrosis: advances, advantages and disadvantages].

    Cequera A et al. · Rev Gastroenterol Mex · 2014 Match 55

    Liver cirrhosis in Mexico is one of the most important causes of…

    FibroTest HCV

  123. The new paradigm of hepatitis C therapy: integration of oral therapies into best practices.

    Afdhal NH et al. · J Viral Hepat · 2013 Match 55

    …recommendations for HCV screening beyond risk-based strategies. Issued in 2012, the…

    ActiTest FibroTest HCV

  124. Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. Key publication

    Poynard T et al. · PLoS One · 2020 Match 54

    …The adjusted risk ratio of apolipoprotein-A1 for survival without transfer to…

    FibroTest COVID

  125. A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation.

    Ahmad W et al. · Virol J · 2011 Match 54

    ### Background Chronic HCV is one of the major causes of morbidity and…

    FibroTest HCV

  126. The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.

    Younossi ZM et al. · Gastroenterology · 2021 Match 54

    …were also associated with increased risk of disease progression in both the…

    FibroTest Metabolic

  127. Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.

    Stevenson M et al. · Health Technol Assess · 2012 Match 53

    …However, as it is an invasive procedure that carries the risk of…

    FibroTest Alcohol

  128. Guidelines for the screening, care and treatment of persons with hepatitis C infection Key publication

    Match 53

    FibroTest HCV

  129. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.

    European Association For The Study Of The Liver · J Hepatol · 2012 Match 52

    ActiTest FibroTest HBV

  130. EASL clinical practical guidelines: management of alcoholic liver disease.

    European Association for the Study of Liver · J Hepatol · 2012 Match 52

    FibroTest Alcohol

  131. Non-invasive diagnosis of hepatitis B virus-related cirrhosis.

    Lee S et al. · World J Gastroenterol · 2014 Match 52

    Chronic hepatitis B (CHB) infection is a major public health problem associated…

    FibroTest HBV

  132. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection

    Match 51

    FibroTest HBV

  133. Ministère des Affaires Sociales et de la Santé Key publication

    Match 51

    FibroTest HBV HCV

Showing the full result list. The page is server-rendered and not paginated.